Alpha-1 antitrypsin (α1AT or AAT) deficiency is another lung and liver disease that has been extensively studied as a target for AAV-mediated gene therapy both in vivo and in humans [284,296]. The gene discussed is SERPINA1; the disease is hyperinsulinemic hypoglycemia, familial, 4.